Study on GLDH combined with liver protection markers or immune markers as biomarkers of liver injury induced by anti-tuberculosis drugs

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051437

Enrollment

Unknown

Registered

2021-09-23

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced liver injury

Interventions

Liver injury group:None

Control group:None

Eligibility

Sex/Gender

All

Age

16 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with tuberculosis; 2. INH and RFP are used, and the use time is more than 7 days; 3. Complete medical records.

Exclusion criteria

Exclusion criteria: 1. Patients with various liver diseases; 2. Abnormal liver function before anti-tuberculosis treatment; 3. AIDS patients or those using immunosuppressants; 4. Pulmonary infection, respiratory failure, malnutrition; 5 Combined with serious cardiovascular, renal, nervous, hematopoietic system diseases and serious diseases that affect their survival (such as tumors, bone marrow suppression, etc.).

Design outcomes

Primary

Measure	Time frame
GLDH;FECH;a-GST;HO-1;SOD;	—

Countries

China

Contacts

Public ContactPeng Wenxing

The Second Xiangya Hospital of Central South University

pwx.csu@csu.edu.cn+86 13755056989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026